First AD

Second AD

Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia

Video content above is prompted by the following:

Briefly comment on data updates presented for the AUGMENT-101 trial.

Given the 64% ORR and 23% CR/CRh rate observed with revumenib in patients with heavily preated pretreated 

-rearranged acute leukemia patients, how do you see this therapy reshaping the treatment landscape for this high-risk population?

Briefly comment on the clinical implications, particularly in the context of bridging to stem cell transplantation.?

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Advancements in the Management of R/R AML: ASH 2024 

Peer Exchange

Panelists discuss the data updates from the AUGMENT-101 trial, the potential of revumenib to reshape the treatment landscape for patients with heavily pretreated KMT2A-rearranged acute leukemia, including its observed objective response rate (ORR) and complete remission (CR)/ CR with partial recovery of peripheral blood counts (CRh) rate, and the clinical implications of revumenib in the context of bridging to stem cell transplantation.